Neuronetics Historical Balance Sheet

STIM Stock

USD 4.36 0.46 11.79%

Trend analysis of Neuronetics balance sheet accounts such as Total Stockholder Equity of 41.3 M, Other Liab of 1.2 M, Net Tangible Assets of 68.9 M or Property Plant And Equipment Net of 3.9 M provides information on Neuronetics' total assets, liabilities, and equity, which is the actual value of Neuronetics to its prevalent stockholders. By breaking down trends over time using Neuronetics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Neuronetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neuronetics is a good buy for the upcoming year.

Neuronetics Inventory

5.04 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.

About Neuronetics Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Neuronetics at a specified time, usually calculated after every quarter, six months, or one year. Neuronetics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Neuronetics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Neuronetics currently owns. An asset can also be divided into two categories, current and non-current.

Neuronetics Balance Sheet Chart

At this time, Neuronetics' Long Term Debt is very stable compared to the past year. As of the 16th of February 2025, Cash And Short Term Investments is likely to grow to about 69.7 M, while Short and Long Term Debt Total is likely to drop about 44.7 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Capital Surpluse

Add Fundamental

Total Assets

Total assets refers to the total amount of Neuronetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neuronetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Neuronetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Neuronetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Neuronetics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Neuronetics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.At this time, Neuronetics' Long Term Debt is very stable compared to the past year. As of the 16th of February 2025, Cash And Short Term Investments is likely to grow to about 69.7 M, while Short and Long Term Debt Total is likely to drop about 44.7 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	39.7M	62.5M	71.8M	44.7M
Total Assets	116.9M	115.8M	133.2M	100.9M

Short Long Term Debt Total Total Assets

Neuronetics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets
Total Assets		0.67	0.72	0.63	0.97	0.55	0.97	0.84	0.83	-0.62	-0.87	0.9	0.95	0.87	0.87	0.43	0.69	0.95	0.72	0.95	0.93	0.6	-0.93	0.97	0.82	0.79
Short Long Term Debt Total	0.67		0.73	0.4	0.55	0.51	0.58	0.64	0.51	-0.02	-0.75	0.78	0.5	0.72	0.67	0.07	0.82	0.5	0.76	0.69	0.74	0.65	-0.48	0.68	0.77	0.78
Other Current Liab	0.72	0.73		0.86	0.64	0.23	0.67	0.75	0.41	-0.15	-0.81	0.62	0.56	0.71	0.65	-0.08	0.61	0.56	0.82	0.76	0.81	0.33	-0.63	0.76	0.88	0.74
Total Current Liabilities	0.63	0.4	0.86		0.63	0.21	0.63	0.78	0.43	-0.27	-0.68	0.48	0.52	0.61	0.56	-0.02	0.32	0.53	0.61	0.67	0.71	0.13	-0.67	0.67	0.69	0.55
Total Stockholder Equity	0.97	0.55	0.64	0.63		0.57	1.0	0.83	0.84	-0.66	-0.84	0.87	0.95	0.81	0.8	0.37	0.63	0.95	0.67	0.94	0.89	0.62	-0.99	0.96	0.73	0.75
Other Liab	0.55	0.51	0.23	0.21	0.57		0.55	0.33	0.85	-0.61	-0.33	0.62	0.67	0.29	0.28	0.22	0.31	0.67	0.17	0.44	0.37	0.8	-0.55	0.47	0.18	0.26
Net Tangible Assets	0.97	0.58	0.67	0.63	1.0	0.55		0.84	0.82	-0.61	-0.87	0.88	0.94	0.83	0.81	0.35	0.68	0.94	0.72	0.96	0.91	0.63	-0.98	0.96	0.75	0.79
Property Plant And Equipment Net	0.84	0.64	0.75	0.78	0.83	0.33	0.84		0.62	-0.28	-0.89	0.8	0.67	0.95	0.91	0.38	0.61	0.68	0.74	0.89	0.96	0.38	-0.83	0.9	0.87	0.8
Current Deferred Revenue	0.83	0.51	0.41	0.43	0.84	0.85	0.82	0.62		-0.74	-0.61	0.76	0.9	0.6	0.63	0.51	0.48	0.91	0.42	0.75	0.65	0.74	-0.8	0.74	0.48	0.53
Net Debt	-0.62	-0.02	-0.15	-0.27	-0.66	-0.61	-0.61	-0.28	-0.74		0.2	-0.42	-0.81	-0.26	-0.32	-0.49	0.04	-0.81	0.04	-0.41	-0.34	-0.36	0.66	-0.52	-0.17	-0.05
Retained Earnings	-0.87	-0.75	-0.81	-0.68	-0.84	-0.33	-0.87	-0.89	-0.61	0.2		-0.79	-0.7	-0.91	-0.88	-0.25	-0.83	-0.71	-0.92	-0.96	-0.94	-0.53	0.8	-0.89	-0.92	-0.94
Accounts Payable	0.9	0.78	0.62	0.48	0.87	0.62	0.88	0.8	0.76	-0.42	-0.79		0.82	0.82	0.77	0.28	0.78	0.82	0.71	0.87	0.87	0.64	-0.83	0.89	0.7	0.8
Cash	0.95	0.5	0.56	0.52	0.95	0.67	0.94	0.67	0.9	-0.81	-0.7	0.82		0.68	0.7	0.43	0.54	1.0	0.54	0.85	0.76	0.62	-0.91	0.87	0.61	0.62
Non Current Assets Total	0.87	0.72	0.71	0.61	0.81	0.29	0.83	0.95	0.6	-0.26	-0.91	0.82	0.68		0.99	0.5	0.71	0.69	0.77	0.89	0.97	0.41	-0.77	0.91	0.92	0.85
Non Currrent Assets Other	0.87	0.67	0.65	0.56	0.8	0.28	0.81	0.91	0.63	-0.32	-0.88	0.77	0.7	0.99		0.62	0.66	0.71	0.71	0.87	0.93	0.4	-0.75	0.89	0.9	0.8
Other Assets	0.43	0.07	-0.08	-0.02	0.37	0.22	0.35	0.38	0.51	-0.49	-0.25	0.28	0.43	0.5	0.62		0.07	0.44	-0.01	0.32	0.34	0.08	-0.31	0.36	0.28	0.17
Long Term Debt	0.69	0.82	0.61	0.32	0.63	0.31	0.68	0.61	0.48	0.04	-0.83	0.78	0.54	0.71	0.66	0.07		0.55	0.92	0.81	0.72	0.6	-0.55	0.67	0.71	0.95
Cash And Short Term Investments	0.95	0.5	0.56	0.53	0.95	0.67	0.94	0.68	0.91	-0.81	-0.71	0.82	1.0	0.69	0.71	0.44	0.55		0.54	0.85	0.77	0.62	-0.92	0.88	0.62	0.63
Net Receivables	0.72	0.76	0.82	0.61	0.67	0.17	0.72	0.74	0.42	0.04	-0.92	0.71	0.54	0.77	0.71	-0.01	0.92	0.54		0.87	0.81	0.45	-0.62	0.74	0.84	0.97
Common Stock Total Equity	0.95	0.69	0.76	0.67	0.94	0.44	0.96	0.89	0.75	-0.41	-0.96	0.87	0.85	0.89	0.87	0.32	0.81	0.85	0.87		0.95	0.6	-0.91	0.95	0.86	0.92
Common Stock Shares Outstanding	0.93	0.74	0.81	0.71	0.89	0.37	0.91	0.96	0.65	-0.34	-0.94	0.87	0.76	0.97	0.93	0.34	0.72	0.77	0.81	0.95		0.51	-0.88	0.97	0.93	0.86
Long Term Debt Total	0.6	0.65	0.33	0.13	0.62	0.8	0.63	0.38	0.74	-0.36	-0.53	0.64	0.62	0.41	0.4	0.08	0.6	0.62	0.45	0.6	0.51		-0.59	0.58	0.4	0.51
Non Current Liabilities Total	-0.93	-0.48	-0.63	-0.67	-0.99	-0.55	-0.98	-0.83	-0.8	0.66	0.8	-0.83	-0.91	-0.77	-0.75	-0.31	-0.55	-0.92	-0.62	-0.91	-0.88	-0.59		-0.94	-0.69	-0.69
Capital Surpluse	0.97	0.68	0.76	0.67	0.96	0.47	0.96	0.9	0.74	-0.52	-0.89	0.89	0.87	0.91	0.89	0.36	0.67	0.88	0.74	0.95	0.97	0.58	-0.94		0.87	0.8
Inventory	0.82	0.77	0.88	0.69	0.73	0.18	0.75	0.87	0.48	-0.17	-0.92	0.7	0.61	0.92	0.9	0.28	0.71	0.62	0.84	0.86	0.93	0.4	-0.69	0.87		0.85
Other Current Assets	0.79	0.78	0.74	0.55	0.75	0.26	0.79	0.8	0.53	-0.05	-0.94	0.8	0.62	0.85	0.8	0.17	0.95	0.63	0.97	0.92	0.86	0.51	-0.69	0.8	0.85

Click cells to compare fundamentals

Neuronetics Account Relationship Matchups

Neuronetics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	78.7M	141.2M	116.9M	115.8M	133.2M	100.9M
Short Long Term Debt Total	38.3M	39.5M	39.7M	62.5M	71.8M	44.7M
Other Current Liab	6.0M	6.9M	13.4M	10.9M	12.6M	9.3M
Total Current Liabilities	13.7M	15.7M	33.2M	19.8M	22.8M	20.5M
Total Stockholder Equity	25.5M	85.2M	57.1M	34.2M	39.3M	41.3M
Other Liab	2.1M	1.7M	1.5M	829K	746.1K	1.2M
Net Tangible Assets	46.7M	25.5M	85.2M	57.1M	65.6M	68.9M
Property Plant And Equipment Net	4.1M	5.1M	5.3M	4.8M	5.5M	3.9M
Current Deferred Revenue	2.0M	2.5M	2.0M	1.6M	1.9M	2.2M
Net Debt	(10.6M)	(54.6M)	(30.6M)	2.8M	2.5M	2.6M
Retained Earnings	(277.5M)	(308.7M)	(345.9M)	(376.1M)	(338.5M)	(355.4M)
Accounts Payable	3.7M	4.3M	2.4M	4.8M	5.5M	3.8M
Cash	49.0M	94.1M	70.3M	59.7M	68.6M	68.7M
Non Current Assets Total	13.6M	25.9M	18.1M	22.0M	25.3M	13.4M
Non Currrent Assets Other	7.2M	19.1M	11.6M	12.4M	14.3M	7.9M
Other Assets	12.9M	167.1M	9.2M	1.0	1.15	1.09
Long Term Debt	34.6M	35.3M	22.8M	59.3M	68.2M	71.6M
Cash And Short Term Investments	50.8M	96.3M	71.9M	60.6M	69.7M	69.7M
Net Receivables	7.2M	7.8M	13.8M	17.8M	20.5M	21.5M
Common Stock Total Equity	177K	186K	191K	273K	314.0K	329.6K
Common Stock Shares Outstanding	18.8M	25.5M	26.9M	28.7M	33.0M	17.5M
Long Term Debt Total	30.4M	19.9M	34.6M	22.8M	26.3M	28.2M
Liabilities And Stockholders Equity	78.7M	141.2M	116.9M	115.8M	133.2M	100.9M
Non Current Liabilities Total	39.5M	40.3M	26.6M	61.8M	55.6M	63.4M
Capital Surpluse	291.9M	297.8M	302.8M	402.7M	463.1M	238.9M
Inventory	3.7M	6.6M	8.9M	8.1M	9.3M	5.0M
Other Current Assets	3.3M	4.6M	4.2M	7.3M	8.4M	8.8M
Other Stockholder Equity	302.8M	393.6M	402.7M	410.0M	471.5M	274.4M
Total Liab	53.2M	56.0M	59.8M	81.6M	73.5M	78.2M
Property Plant And Equipment Gross	4.1M	5.1M	5.3M	7.6M	8.7M	9.2M
Total Current Assets	65.0M	115.3M	98.8M	93.8M	107.9M	87.4M
Short Term Debt	1.2M	1.3M	14.8M	1.7M	1.5M	1.4M
Common Stock	191K	264K	273K	291K	334.7K	190.6K
Property Plant Equipment	4.9M	730K	5.1M	2.0M	2.3M	2.7M
Net Invested Capital	60.1M	120.5M	93.0M	93.5M	107.5M	60.4M
Net Working Capital	51.3M	99.6M	65.6M	74.0M	85.1M	75.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Neuronetics is a strong investment it is important to analyze Neuronetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuronetics' future performance. For an informed investment choice regarding Neuronetics Stock, refer to the following important reports:

How To Invest In Neuronetics

Details

Is Neuronetics Stock a good investment?

Details

What is Neuronetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.

You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.22)

Revenue Per Share

2.446

Quarterly Revenue Growth

0.036

Return On Assets

(0.19)

Return On Equity

(1.54)

The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neuronetics Historical Balance Sheet

Neuronetics Inventory

5.04 Million

About Neuronetics Balance Sheet Analysis

Neuronetics Balance Sheet Chart

Total Assets

Total Current Liabilities

Neuronetics balance sheet Correlations

Neuronetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neuronetics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Total Stockholder Equity	+ 0.97	Total Assets
Net Tangible Assets	+ 0.97	Total Assets
Capital Surpluse	+ 0.97	Total Assets

Non Current Liabilities Total	- 0.99	Total Stockholder Equity
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Common Stock Total Equity	- 0.96	Retained Earnings
Capital Surpluse	- 0.94	Non Current Liabilities Total
Other Current Assets	- 0.94	Retained Earnings
Common Stock Shares Outstanding	- 0.94	Retained Earnings